Format

Send to

Choose Destination
Lancet. 1996 Jul 6;348(9019):27-9.

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate.

Author information

1
Antrim Hospital, UK.

Abstract

BACKGROUND:

Fluticasone propionate was introduced in 1993 in the UK as a potentially safer inhaled corticosteroid than those already in use. The efficacy and safety of fluticasone has been established at recommended doses of 200 micrograms/day, but not at higher doses that are often used.

METHODS:

Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder). Assessment of cortisol response was by insulin-induced hypoglycaemia in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one.

FINDINGS:

Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression. In one case the growth rate and cortisol response returned to normal 9 months after the fluticasone dose was reduced to 500 micrograms/day.

INTERPRETATION:

When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.

PMID:
8691927
DOI:
10.1016/s0140-6736(96)03339-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center